Patents by Inventor Robert Raya
Robert Raya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11492411Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: November 4, 2019Date of Patent: November 8, 2022Assignee: Amgen Fremont Inc.Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R. F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20200062860Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: November 4, 2019Publication date: February 27, 2020Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R.F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 10508153Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: June 18, 2015Date of Patent: December 17, 2019Assignee: Amgen Fremont Inc.Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R. F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 10118968Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: December 29, 2009Date of Patent: November 6, 2018Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20150315288Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: June 18, 2015Publication date: November 5, 2015Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R.F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 9096672Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: March 2, 2009Date of Patent: August 4, 2015Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 9085624Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: November 10, 2008Date of Patent: July 21, 2015Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 9073998Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: March 2, 2009Date of Patent: July 7, 2015Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 9062113Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: November 10, 2008Date of Patent: June 23, 2015Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 7736644Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: June 25, 2004Date of Patent: June 15, 2010Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20100111979Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: December 29, 2009Publication date: May 6, 2010Applicant: AMGEN FREMONT INC.Inventors: RICHARD WEBER, XIAO FENG, ORIT FOORD, LARRY GREEN, JEAN M. GUDAS, BRUCE KEYT, YING LIU, PALANISWAMI RATHANASWAMI, ROBERT RAYA, XIAO DONG YANG, JOSE CORVALAN, IAN FOLTZ, XIAO-CHI JIA, JASPAL S. KANG, CHADWICK T. KING, SCOTT L. KLAKAMP, QIAOJUAN JANE SU
-
Patent number: 7628986Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: June 25, 2004Date of Patent: December 8, 2009Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20090240038Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: March 2, 2009Publication date: September 24, 2009Applicant: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20090175887Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: March 2, 2009Publication date: July 9, 2009Applicant: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20090156790Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: November 10, 2008Publication date: June 18, 2009Applicant: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20090155282Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: November 10, 2008Publication date: June 18, 2009Applicant: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Publication number: 20050059087Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: June 25, 2004Publication date: March 17, 2005Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Kang, Chadwick King, Scott Klakamp, Qiaojuan Su
-
Publication number: 20050053608Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: ApplicationFiled: June 25, 2004Publication date: March 10, 2005Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Kang, Chadwick King, Scott Klakamp, Qiaojuan Su